Search Within

Jonathan Eric Rosenberg

Formats
  1. Meeting Abstract (283)
  2. Journal Article (195)
  3. Review (18)
  4. Correspondence (10)
  5. Editorial (5)
  6. Guidelines (4)
  7. Book Section (2)
  8. Research Letter (2)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (520)
  2. Genitourinary Oncology Service (520)
  3. Solid Tumor Oncology Division (520)
  4. Department of Pathology and Laboratory Medicine (149)
  5. Surgery (140)
  6. Urology (137)

More Groups

People
  1. Dean Bajorin (204)
  2. Gopakumar Iyer (175)
  3. Hikmat Al-Ahmadie (134)
  4. Bernard Bochner (124)
  5. David Solit (114)
  6. Min Yuen Teo (75)

More People

Years
  1. 2025 (23)
  2. 2024 (36)
  3. 2023 (32)
  4. 2022 (36)
  5. 2021 (48)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (204)
  2. Annals of Oncology (42)
  3. European Urology (20)
  4. Clinical Genitourinary Cancer (18)
  5. Clinical Cancer Research (16)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (210)
  2. Oxford University Press (47)
  3. Elsevier Inc. (39)
  4. Elsevier Science, Inc. (36)
  5. Nature Publishing Group (36)
  6. American Association for Cancer Research (35)

More Publishers

Results (520)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase Ill trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Ballman, K. V.; Halabi, S.; Watt, C.; Hahn, O. M.; Steen, P. D.; Dreicer, R.; Flaig, T. W.; Stadler, W. M.; Sweeney, C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Pretreatment eosinophil counts (PEC) in metastatic urothelial carcinoma (mUC) treated with anti-PD1/PD-L1 checkpoint inhibitors (CPI)
    Meeting Abstract

    Mota, J. M.; Teo, M. Y.; Whiting, K.; Ostrovnaya, I.; Li, H.; Lee, C. H.; Funt, S. A.; Callahan, M. K.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Durability of complete response (CR) with atezolizumab (atezo) in locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Loriot, Y.; Balar, A. V.; Dreicer, R.; Hoffman-Censits, J. H.; Perez-Gracia, J. L.; Petrylak, D. P.; Van der Heijden, M. S.; Shen, X.; Zhu, Q.; Ding, B.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer
    Meeting Abstract

    Hoimes, C. J.; Rosenberg, J. E.; Petrylak, D. P.; Carret, A. S.; Melhem-Bertrandt, A.; Flaig, T. W.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results
    Meeting Abstract

    Dizman, N.; Rosenberg, J. E.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets
    Meeting Abstract

    Bandini, M.; Pederzoli, F.; Madison, R.; Briganti, A.; Plimack, E. R.; Ross, J. S.; Niegisch, G.; Yu, E. Y.; Bamias, A.; Agarwal, N.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors
    Meeting Abstract

    Sonpavde, G.; Hennessy, D.; Manitz, J.; Niegisch, G.; Powles, T.; Rosenberg, J. E.; Bajorin, D. F.; Apolo, A. B.; Pond, G. R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends
    Meeting Abstract

    Rosenthal, K.; Galsky, M. D.; Milowsky, M. I.; Petrylak, D. P.; Rosenberg, J. E.; Obholz, K.; Plimack, E. R.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • EV-301: Phase Ill study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (Ia/mUC)
    Meeting Abstract

    Petrylak, D. P.; Rosenberg, J. E.; Duran, I.; Loriot, Y.; Sonpavde, G.; Wu, C.; Gartner, E. M.; Melhem-Bertrandt, A.; Powles, T.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save